C90.0 C90.3
Conditions
Interventions
Group 1: Patient inclusion at initial diagnosis with prospective data acquisition
Group 2: Patient inclusion at therapy change with retrospective data acquisition of previous therapies and prospectiv
Sponsors
Universitätsklinikum Rostock
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with multiple myeloma (including extraosseous plasmocytoma, solitary plasmocytoma of the bone, smouldering myeloma). a. At the time of the initial diagnosis in patients with myeloma requiring treatment or multiple myeloma requiring treatment b. At the time of a change in therapy in patients with multiple myeloma requiring treatment 2. Presence of a declaration of consent
Exclusion criteria
Exclusion criteria: 1. Non-consenting patients 2. Simultaneous participation of patients in another myeloma registry supported by the participating pharmaceutical companies 3. Diagnosis of a monoclonal gammopathy of unclear significance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Description of patients with multiple myeloma in need of therapy with regard to age, concomitant diseases, myeloma subtype and other demographic data - Clinical or laboratory parameters that determine the initiation or Reasons for changing myeloma-specific therapy in everyday life, time latency between diagnosis and start of therapy - Frequency of determination of cytogenetic and molecular genetic risk parameters outside clinical studies and their influence on the choice of therapy - Description of the therapy protocols used for primary and recurrent therapy, usual therapy sequences, necessity of dose modifications, indication for the use of autologous or allogeneic blood stem cell transplantation, maintenance therapy and consolidation therapy strategies - effectiveness of the selected therapy protocols (response, progression-free survival, overall survival), influence of the response on the further therapy strategy (therapy intensification, consolidation strategy, maintenance or therapy pause) - occurrence of side effects, including severe side effects | — |
Countries
Germany
Contacts
Public ContactSebastian Böttcher
Universitätsklinikum Rostock
Outcome results
None listed